Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$25.16

-0.12 (-0.47%)

, GEMP

Gemphire Therapeutics

$9.70

-0.11 (-1.12%)

07:55
02/23/17
02/23
07:55
02/23/17
07:55

RBC Capital to hold a conference

Global Healthcare Conference is being held in New York on February 22-23 with webcasted company presentations to begin on February 23 at 8 am; not all company presentations may be webcasted. Webcast Link

BSX

Boston Scientific

$25.16

-0.12 (-0.47%)

GEMP

Gemphire Therapeutics

$9.70

-0.11 (-1.12%)

VEC

Vectrus

$22.90

-0.18 (-0.78%)

OCUL

Ocular Therapeutix

$8.32

-0.8 (-8.77%)

BTG

B2Gold

$3.35

0.05 (1.52%)

JNJ

Johnson & Johnson

$119.52

-0.14 (-0.12%)

NEOS

Neos Therapeutics

$5.65

-0.15 (-2.59%)

MDT

Medtronic

$79.62

-0.94 (-1.17%)

GEN

Genesis Healthcare

$3.83

-0.05 (-1.29%)

OPK

OPKO Health

$8.45

-0.19 (-2.20%)

SPPI

Spectrum

$5.75

-0.09 (-1.54%)

AXSM

Axsome Therapeutics

$4.30

-0.05 (-1.15%)

CTMX

CytomX Therapeutics

$11.74

-0.19 (-1.59%)

INSY

Insys Therapeutics

$13.48

0.83 (6.56%)

ZIOP

ZIOPHARM

$6.74

-0.08 (-1.17%)

ACOR

Acorda Therapeutics

$25.25

-0.05 (-0.20%)

  • 23

    Feb

  • 23

    Feb

  • 24

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 01

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 09

    Mar

  • 14

    Mar

  • 17

    Mar

  • 21

    Mar

  • 27

    Mar

  • 04

    May

  • 19

    Jul

BSX Boston Scientific
$25.16

-0.12 (-0.47%)

01/03/17
JPMS
01/03/17
NO CHANGE
JPMS
JPMorgan predicts more challenging 2017 for MedTechs
JPMorgan laid out its top picks for 2017 in the Medical Technology space despite predicting a "challenging" year for the sector. A rising interest rate and rising dollar environment, combined with lower top-line growth on tough first half comparisons, are likely to make 2017 outperformance harder to come by, the firm earlier today in a research note. JPMorgan believes the headwinds could change into the second half of 2017, however. Among large-caps, the firm likes Boston Scientific (BSX) and Edwards Lifesciences (EW). Among small-caps, the firm's top picks are iRhythm Technologies (IRTC) and Nevro (NVRO).
12/02/16
LEER
12/02/16
NO CHANGE
LEER
Outperform
Neovasc's Boston Scientific deal provides a reprieve, says Leerink
Leerink analyst Danielle Antalffy said Neovasc (NVCN) share are reacting positively to the announcement that Boston Scientific (BSX) is aquiring tissue manufacturing assets and a 15% stake on the company for $75M. The analyst said the deal significantly improves its ability to continue to operate regardless of the outcome of ongoing litigation and believes the likelihood that Neovasc can continue to operate has increased substantially. Antalffy rates Neovasc an Outperform.
09/01/16
09/01/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Boston Scientific (BSX) upgraded to Buy from Hold at Argus by analyst David Toung, who believes that the company reported "strong" Q2 sales and is gaining share. 2. WEX Inc. (WEX) upgraded to Outperform from Underperform at CLSA by analyst Tom McCrohan who increased his average fuel price outlook, which resulted in an increase in earnings contribution of approximately 30c per share for both 2017 and 2018. Additionally, the analyst said management is beginning to implement higher late fees on its small business clients, which can unlock 90c per share of additional earnings power as small fleet customers incur higher late fees on overdue balances. 3. Nomura (NMR) upgraded to Hold from Underperform at Jefferies by analyst Makarim Salman, who still cautions investors not to "chase the momentum" following the company's positive Q1 earnings. 4. Seacoast Banking (SBCF) upgraded to Outperform from Market Perform at Keefe Bruyette by analyst Jefferson Harralson, who thinks the company is about to "ramp to a meaningfully higher profitability" following its efficiency improvements. 5. Randgold (GOLD) upgraded to Buy from Hold at Canaccord, citing valuation following its Q2 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/14/17
WELS
02/14/17
NO CHANGE
WELS
Medtronic data likely to be positive, says Wells Fargo
Wells Fargo predicts that data on Medtronic's (MDT) CoreValve/Evolut R, due to be presented on March 17, will show that the device "is superior to surgical aortic valve replacement in intermediate risk patients." If the results come in as expected, the device should be approved in the U.S. by early fall, according to the firm. Wells Fargo adds that the data should also be a positive for other TAVR stocks, including Edwards Lifesciences (EW) and Boston Scientific (BSX). Wells keeps Outperform ratings on all three stocks.
GEMP Gemphire Therapeutics
$9.70

-0.11 (-1.12%)

08/30/16
ADAM
08/30/16
INITIATION
Target $17
ADAM
Buy
Gemphire Therapeutics initiated with a Buy at Canaccord
Canaccord Genuity analyst John Newman started Gemphire Therapeutics with a Buy rating and $17 price target. The company's oral cholesterol drug gemcabene has a $2.8B U.S. peak market potential, Newman tells investors in a research note.
08/30/16
JEFF
08/30/16
INITIATION
Target $15
JEFF
Buy
Gemphire Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Matthew Andrews started Gemphire Therapeutics with a Buy rating and $15 price target. The company's gemcabene has a favorable profile in the broad dyslipidemia market, Andrews tells investors in a research note.
08/30/16
RBCM
08/30/16
INITIATION
Target $25
RBCM
Outperform
Gemphire Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Adnan Butt started Gemphire Therapeutics with an Outperform rating and $25 price target.
08/30/16
08/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BofA Merrill Lynch resumed coverage on Hershey (HSY) with an Underperform rating and $100 price target, as the firm expects shares to trade on fundamentals, which are under pressure. Last night, Mondelez (MDLZ) announced it has ended discussions with Hershey regarding a possible combination of the two companies. 2. eBay (EBAY) initiated with a Long-Term Buy at Hilliard Lyons by analyst Stephen Turner , who set a $35 price target on the stock. 3. Galapagos NV (GLPG) initiated with a Buy at Janney Capital by Debjit Chattopadhyay, who said that filgotinib, the company's oral JAK inhibitor, is "shaping up to be a blockbuster." 4. Gemphire Therapeutics (GEMP) initiated with with a Buy rating and $17 price target by Canaccord Genuity analyst John Newman and with a Buy rating and $15 price target by Jefferies analyst Matthew Andrews. 5. Sophiris Bio (SPHS) initiated with an an Overweight rating and $7 price target by Piper Jaffray analyst Charles Duncan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VEC Vectrus
$22.90

-0.18 (-0.78%)

03/16/16
SIDC
03/16/16
DOWNGRADE
SIDC
Neutral
Vectrus downgraded to Neutral from Buy at Sidoti
09/29/16
STFL
09/29/16
INITIATION
Target $30
STFL
Hold
Vectrus initiated with a Hold at Stifel
Stifel initiated Vectrus with a Hold and a $30 price target.
OCUL Ocular Therapeutix
$8.32

-0.8 (-8.77%)

01/20/17
BTIG
01/20/17
NO CHANGE
Target $13
BTIG
Buy
Ocular Therapeutix price target lowered to $13 from $18 at BTIG
BTIG analyst Dane Leone took over coverage of Ocular Therapeutix with a Buy rating and $13 price target, down from the prior $18 target of analyst Ling Wang, stating that missed study endpoints have significantly reduced investor forecasts and valuation over the past 18 months. That said, Leone believes expectations and valuation have now been sufficiently reset to provide upside.
10/13/16
BTIG
10/13/16
NO CHANGE
Target $18
BTIG
Buy
Ocular deal with Regeneron has favorable terms, says BTIG
BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target
02/09/17
CANT
02/09/17
INITIATION
Target $35
CANT
Overweight
Ocular Therapeutix initiated with an Overweight at Cantor
Cantor initiated Ocular Therapeutix with an Overweight and a $35 price target.
02/10/17
02/10/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Symantec (SYMC) reinstated with an Equal Weight at Barclays. 2. Discovery (DISCA) and AMC Networks (AMCX) were initiated with a Hold at Deutsche Bank. 3. Ocular Therapeutix (OCUL) initiated with an Overweight at Cantor. 4. MarineMax (HZO) initiated with a Buy at Citi. 5. Williams Partners (WPZ) was initiated with a Buy at Deutsche Bank, while Williams (WMB) was initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BTG B2Gold
$3.35

0.05 (1.52%)

05/13/16
RBCM
05/13/16
NO CHANGE
RBCM
B2Gold reported 'strong' Q1 results, says RBC Capital
RBC Capital says that B2Gold reported "strong" Q1 results, and the firm thinks that the company's costs could continue to drop going forward. RBC raised its price target on the name to $3.50 from $3. It says that the stock's valuation is attractive and keeps an Outperform rating on the shares.
09/20/16
DUND
09/20/16
UPGRADE
DUND
Buy
B2Gold upgraded to Buy from Neutral at Dundee
JNJ Johnson & Johnson
$119.52

-0.14 (-0.12%)

02/02/17
JEFF
02/02/17
NO CHANGE
Target $53
JEFF
Buy
Jefferies sees J&J deal as not prohibiting Pacira takeover
Jefferies analyst David Steinberg says that after meeting with management, he has greater confidence that Pacira Pharmaceuticals' (PCRX) collaboration with Johnson & Johnson (JNJ) offers an opportunity for the company to meaningfully broaden the promotion of Exparel in surgical suites and potentially reaccelerate revenue starting in the second half of 2017. The analyst adds that his sense is the J&J partnership would not stand in the way of any potential takeover. Management did not disclose any stand-still or change of control provisions in its arrangement with J&J, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Pacira with a $53 price target.
01/31/17
01/31/17
NO CHANGE

Deutsche sees label warnings as worst case for Actelion drug
After France's National Agency for the Safety of Medicines and Health Products, in a letter dated January 24, asked doctors to stop treating new patients with Actelion's (ALIOF) Uptravi as it investigates patient deaths, Deutsche Bank said it believes a label warnings for the pulmonary arterial hypertension drug is likely the worst case scenario. The firm thinks Johnson & Johnson (JNJ) likely knew of the letter before reaching an agreement to acquire Actelion. Shares of Actelion are down 4% to $65.40 in morning trading.
02/16/17
OPCO
02/16/17
NO CHANGE
OPCO
Outperform
Codman acquisition strengths Integra neurosurgery position, says Oppenheimer
Following the announcement that Integra LifeSciences (IART) acquired the Codman Neurosurgery Business from Johnson & Johnson (JNJ), Oppenheimer analyst Steven Lichtman says the addition brings complementary products to further strengthen the former's position in the neurosurgery market. Additionally, the analyst notes that the deal also expands Integra LifeSciences' international revenue and adds to the company's international infrastructure that will be supportive primarily of its neurosurgery business, but will also help in the international build-out of other segments. He reiterates an Outperform rating on Integra LifeSciences' shares.
02/17/17
RBCM
02/17/17
NO CHANGE
Target $105
RBCM
Outperform
Edgewell Personal Care remains takeout target, says RBC Capital
After Kraft Heinz (KHC) confirmed it had approached Unilever (UN, UL) with a merger proposal, RBC Capital analyst Nik Modi says the news come as a surprise, but does not warrant a change in his Edgewell Personal Care (EPC) takeout thesis. The analyst reiterates an Outperform rating on the latter's shares, with a $105 price target, on improving margin and revenue profile and the prospects of a takeout in the next 12-16 months, with Unilever as one of the more likely buyers. Other potential suitors include Kimberly-Clark (KMB), Beiersdorf, Henkel, Johnson & Johnson (JNJ), Colgate-Palmolive (CL), Church & Dwight (CHD), L'Oreal (LRLCY), and Kao, he adds.
NEOS Neos Therapeutics
$5.65

-0.15 (-2.59%)

06/28/16
BMOC
06/28/16
INITIATION
Target $15
BMOC
Outperform
Neos Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Gary Nachman started Neos Therapeutics with an Outperform rating and $15 price target.
06/29/16
06/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Valeant (VRX) initiated with a Market Perform at BMO Capital by analyst Gary Nachman, who set a $26 price target on the stock. The analyst also initiated Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Flexion (FLXN) and Neos Therapeutics (NEOS) with Outperform ratings and Endo (ENDP), Impax (IPXL) and Amphastar (AMPH) with Market Perform ratings. 2. Regeneron (REGN) initiated with an Outperform rating and $400 target at Bernstein. The firm expects the sales of the company's Praluent drug to accelerate, and it believes that the shares have reached an attractive entry point following their steep decline since 2015. Bernstein also initiated Biogen (BIIB) with an Outperform rating and $282 target. 3. Newfield Exploration (NFX) initiated with a Buy at Canaccord by analyst Stephen Berman, citing its leading position in the Anadarko Basin SCOOP and STACK plays of Oklahoma, solid balance sheet, and cost efficiencies. Canaccord has a $48 price target on Newfield Exploration shares. 4. Fleetmatics (FLTX) initiated with an Overweight at Morgan Stanley by analyst James Faucette, who put a $52 price target on the stock. The analyst said improved commercial vehicle utilization is an underappreciated market opportunity and believes the company is well positioned to expand its value proposition and drive market adoption and up-sell subscriptions. Fleetmatics was also initiated with an Outperform rating and $52 target at Baird. 5. Pure Storage (PSTG) initiated with a Neutral at Baird as they sit on the sidelines waiting for clarity on the company's market share trajectory. Baird has a $12 price target on Pure Storage shares. Pure Storage was also initiated with an Outperform rating and $15 price target at Macquarie by analyst Rajesh Ghai. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/19/16
UBSW
05/19/16
NO CHANGE
Target $14
UBSW
Buy
Neos Therapeutics price target lowered to $14 from $22 at UBS
UBS lowered its price target on Neos Therapeutics to $14 from $22 citing the recent weakness due to the delay in approval of Contempla, the announcement of a potential secondary, which was subsequently withdrawn, and multiple contraction across the sector. UBS maintained its Buy rating on Neos shares.
08/12/16
BMOC
08/12/16
NO CHANGE
Target $15
BMOC
Outperform
Neos Therapeutics selloff yesterday overdone, says BMO Capital
BMO Capital analyst Gary Nachman said he believes the selloff yesterday in shares of Neos Therapeutics was overdone and noted that the trend in Adzenys XR-ODT prescriptions continues to get better. Nachman, who sees the upcoming back-to-school season as a major inflection point, keeps an Outperform rating and $15 price target on Neos.
MDT Medtronic
$79.62

-0.94 (-1.17%)

02/23/17
LEER
02/23/17
NO CHANGE
Target $85
LEER
Market Perform
Medtronic price target raised to $85 from $80 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Medtronic to $85 from $80 after the company delivered what he believes was an "encouraging rebound" quarter after an unexpected Q2 miss. While the analyst remains cautious on the company's ability to manage through what could be meaningful top-line headwinds in Q4 and FY18 in order to deliver a targeted mid-single-digit sales growth, it does seem that the diversified business model gives it a cushion with which to offset underperforming business segments with stronger/faster growth elsewhere. He reiterates a Market Perform rating on the shares.
02/15/17
DBAB
02/15/17
NO CHANGE
Target $96
DBAB
Buy
Medtronic shares have more upside, says Deutsche Bank
Deutsche Bank analyst Kristen Stewart says the recent stock appreciation has not changed her bullish view on Medtronic. Ahead of the company's Q3 results on February 21, Stewart sees more upside in the stock. She keeps a Buy rating on Medtronic with a $96 price target.
02/22/17
NEED
02/22/17
NO CHANGE
Target $91
NEED
Buy
Medtronic price target raised to $91 from $84 at Needham
Needham analyst Mike Matson raised his price target for Medtronic to $91 from $84 after Q3 revenue and EPS beat consensus and the company maintained its 2017 guidance. The analyst believes the shares remain at a discount to peers and reiterates a Buy rating on the stock.
GEN Genesis Healthcare
$3.83

-0.05 (-1.29%)

05/16/16
05/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bitauto (BITA) downgraded to Underweight at Morgan Stanley by analyst Amanda Chen, who cited the slowdown in the ad and subscription business, aggressive transaction monetization that could result in dealer push back, and less transparent disclosures. 2. Genesis Healthcare (GEN) downgraded to Underperform at BofA/Merrill citing reduced guidance, industry wide pressures and low debt coverage. 3. Bank of America (BAC) downgraded to Market Perform at Keefe Bruyette by analyst Brian Kleinhanzl, who said the bank has more work to do to improve returns and drive shareholder value higher longer term. 4. UBS (UBS )double downgraded to Underperform at Keefe Bruyette with a price target of CHF 16. 5. Deutsche Bank (DB) downgraded to Sell at Berenberg citing leverage concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/16
RBCM
11/21/16
DOWNGRADE
RBCM
Sector Perform
Genesis Healthcare downgraded to Sector Perform from Outperform at RBC Capital
11/21/16
RBCM
11/21/16
DOWNGRADE
RBCM
Sector Perform
Genesis downgraded on challenges, divestitures, valuation at RBC Capital
As noted earlier, RBC Capital downgraded Genesis Healthcare to Sector Perform from Outperform. After the company reported slightly weaker than expected Q3 results, analyst Frank Morgan says that industry difficulties are continuing to cause operational challenges for the company. He thinks that these challenges, combined with the company's divestiture from eight states, could "cause bumpiness in its 2017 results." Target to $3.50 from $3.
05/16/16
BOFA
05/16/16
DOWNGRADE
Target $1.8
BOFA
Underperform
Genesis Healthcare downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded Genesis Healthcare to Underperform citing reduced guidance, industry wide pressures, and low debt coverage, among other reasons. The firm cut Genesis' price target to $1.80 from $2.30.
OPK OPKO Health
$8.45

-0.19 (-2.20%)

01/18/17
ADAM
01/18/17
NO CHANGE
Target $18
ADAM
Buy
Natera selloff overdone, says Canaccord
Canaccord analyst Mark Massaro noted Natera (NTRA) sold off following its decision to terminate its contract with Bio Reference Labs (OPK) as well as President-elect Trump's comment that he will force the biotech and pharma industry to negotiate with the government on CMS prices. Although the contract absence is a near-term negative, the comments from Trump have nothing to do with Natera. As a result, Massaro believes the selloff in Natera shares is overdone. Massaro reiterated his Buy rating and $18 price target on Natera shares.
01/03/17
BRRR
01/03/17
NO CHANGE
Target $15
BRRR
Outperform
Selling OPKO Friday likely a mistake, says Barrington
Investors who sold shares of OPKO Health on Friday's news likely made a mistake, Barrington analyst Michael Petusky tells investors in a research note. The analyst does not believe Pfizer (PFE) would have agreed to the language in the OPKO press release that cited "one or more outliers" if this were not a potentially game-changing issue. Petusky keeps an Outperform rating on shars of OPKO with a $15 price target.
12/30/16
STPT
12/30/16
NO CHANGE
Target $18
STPT
Buy
OPKO Health selloff an overreaction, says Standpoint Research
After speaking with the company's CEO Phillip Frost, Standpoint Research says today's selloff in the shares of OPKO Health is an overreaction. The stock is down 16% to $9.65. Standpoint expects today's bad news to be reversed in the next six to 12 weeks. The firm reiterates a Buy rating on the shares with an $18 price target.
01/10/17
PIPR
01/10/17
NO CHANGE
PIPR
Overweight
Natera distribution pact termination a positive, says Piper Jaffray
Piper Jaffray analyst William Quirk said Natera's (NTRA) termination of a distribution agreement with Bio-Reference Laboratories, which has been acquired by OPKO Health (OPK), is a positive for Natera as the company has many payer contracts in place and has successfully transitioned a series of physicians to a direct model in the past. Natera will now directly market Panorama to clinicians as well as market Horizon to them, which Bio-Reference had not previously done, said Quirk, who keeps an Overweight rating on Natera shares.
SPPI Spectrum
$5.75

-0.09 (-1.54%)

02/10/17
JEFF
02/10/17
UPGRADE
Target $7.5
JEFF
Buy
Spectrum assumed with a Buy from Hold at Jefferies
Jefferies analyst Matthew Andrews upgraded Spectrum Pharmaceuticals to Buy after assuming coverage of the name. The stock is undervalued based on Rolontis' long-term promise in chemotherapy-induced neutropenia, Andrews tells investors in a research note. The analyst sees 50%-plus share upside on expectations that Rolontis is lower risk and should gain meaningful market share from Neulasta. He has a $7.50 price target for Spectrum.
09/14/16
FBRC
09/14/16
NO CHANGE
FBRC
Spectrum selloff a buying opportunity, says FBR Capital
FBR Capital recommends buying shares of Spectrum Pharmaceuticals on today's selloff following the negative FDA panel vote.
04/21/16
ROTH
04/21/16
NO CHANGE
Target $147
ROTH
Buy
Roth Capital remains a buyer of Ligand Pharmaceuticals
Roth Capital analyst Joseph Pantgini remains a buyer of Ligand Pharmaceuticals (LGND) after Spectrum's (SPPI) Evomela received Orphan status by the FDA providing seven years of market exclusivity. The analyst noted that Ligand is entitled to a 20% royalty on Evomela revenue. Pantgini expects that current revenue streams from partnered products and the broad "in development" portfolio will drive "significant" growth in the near and longer term. The analyst reiterates a Buy rating and $147 price target on Ligand's shares.
09/15/16
RBCM
09/15/16
NO CHANGE
RBCM
Spectrum apaziquone can still be approved, says RBC Capital
After the FDA's cancer drug advisory panel voted against Spectrum's apaziquone, RBC Capital analyst Adrian Butt continues to believe that the drug could fulfill an unmet need. Buttr says that the company should continue its third Phase 3 study of the drug, and the analyst thinks that the drug could be approved down the road if the data is positive. Butt lowered the price target on Spectrum to $10 from $11 but keeps an Outperform rating on the shares.
AXSM Axsome Therapeutics
$4.30

-0.05 (-1.15%)

10/03/16
BMUR
10/03/16
INITIATION
Target $20
BMUR
Buy
Axsome Therapies coverage assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage on Axsome Therapies with a Buy rating citing various value drivers that possess lower than average risks and a proven business model that lends itself to a shorter line to commercialization. Yang placed a $20 price target on Axsome Therapies, which was reduced from the firm's prior price target of $29.
CTMX CytomX Therapeutics
$11.74

-0.19 (-1.59%)

01/03/17
OPCO
01/03/17
DOWNGRADE
OPCO
Perform
CytomX Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann downgraded CytomX Therapeutics to Perform citing valuation. The analyst's model assumes only one of the company's experimental therapies has a revenue impact between 2016 and 2025.
INSY Insys Therapeutics
$13.48

0.83 (6.56%)

07/05/16
JANY
07/05/16
NO CHANGE
Target $22
JANY
Buy
Insys approval of Syndros may trigger short squeeze, says Janney Capital
Janney Capital analyst Ken Trbovich said in a note published on July 1 that the potential approval of Syndros was one of three potential catalysts expected in the next six months that may trigger a short squeeze in shares of Insys Therapeutics. Insys announced this morning that the FDA has approved Syndros for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. In his prior note, Trbovich set a $22 fair value estimate and Buy rating on Insys shares, which are up 20% to $16.18 in pre-market trading.
08/04/16
JEFF
08/04/16
NO CHANGE
Target $22
JEFF
Buy
Insys Therapeutics price target raised to $22 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Insys Therapeutics to $22 saying Subsys scripts appear to have stabilized following the company's in-line Q2 results. The most important element of earnings call was the comment that "we're very optimistic that it [settlement with the DOJ] could happen by end of the year," Steinberg tells investors in a research note. The analyst views the Department of Justice investigation as "by far the most important overhang to the story." He keeps a Buy rating on Insys.
08/26/16
JANY
08/26/16
NO CHANGE
Target $22
JANY
Buy
Illinois 'highly unlikely' to be able to bar Insys sales, says Janney Capital
Janney Capital analyst Ken Trbovich said he thinks it is "highly unlikely" that Illinois' Attorney General will succeed with her proposal to ban Insys Therapeutics from doing business in the state, pointing to the fact that a similar attempt by Massachusetts in 2014 was struck down by a federal judge. This story, and the trading in its wake yesterday, clearly indicate Insys has headline risks from ongoing state and federal investigations, acknowledged Trbovich, but he thinks the risk will be eliminated by a settlement for an amount the company can manage from its existing cash. The analyst keeps a Buy rating and $22 fair value estimate on Insys shares, which fell about 4.6% yesterday to close at $14.98.
01/18/17
OPCO
01/18/17
NO CHANGE
OPCO
Perform
Insys settlement with DOJ may be nearing, says Oppenheimer
Oppenheimer analyst Derek Archila said his recent diligence with a former federal prosecutor leads him to believes that Insys Therapeutics may be nearing a settlement with the DOJ. Resolving the ongoing DOJ investigation would clear the company's major overhang and shares could rally on the announcement, said Archila, though he prefers to stay on the sideline and keeps a Perform rating on the stock, citing the risk he sees to Subsys sales and his belief that consensus Syndros sales estimates are too high.
ZIOP ZIOPHARM
$6.74

-0.08 (-1.17%)

06/02/16
RAJA
06/02/16
INITIATION
RAJA
Market Perform
ZIOPHARM initiated with a Market Perform at Raymond James
07/15/16
JMPS
07/15/16
NO CHANGE
Target $42
JMPS
Outperform
JMP says ZIOPHARM trial death doesn't read through to other Intrexon programs
JMP Securities analyst Jason Butler said he views the patient death in ZIOPHARM's (ZIOP) Ad-RTS-IL-12 GBM trial as "possibly or even likely due to the study drug" and acknowledges the need for caution regarding the potential safety concerns of Ad-RTS-IL-12. However, while the trial death raises questions, Butler contends it has no read through to partner Intrexon's (XON) broader oncology programs. The analyst, who notes there are multiple other programs in or entering the clinic under the collaborations between ZIOPHARM and Intrexon, keeps an Outperform rating and $42 price target on Intrexon shares.
08/10/16
WELS
08/10/16
UPGRADE
WELS
Market Perform
ZIOPHARM upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded ZIOPHARM Oncology to Market Perform citing valuation following the company's Q2 results. The analyst keeps a $5-$8 price target range for the shares.
ACOR Acorda Therapeutics
$25.25

-0.05 (-0.20%)

02/15/17
02/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Parker-Hannifin (PH) upgraded to Buy from Neutral at BofA/Merrill, with analyst Andrew Obin saying he sees significant earnings upside in the coming years from cyclical upside from an industrial recovery combined with the operating turnaround story and integration of Clarcor. 2. Nordson (NDSN) upgraded to Overweight from Sector Weight at KeyBanc, with analyst Jeffrey Hammond saying that despite concerns, he believes Nordson's Advanced Technology story has legs given improving semiconductor capex in 2017, meaningful business wins with Chinese smartphone makers pushing for greater automation, and diversification through on-wafer dispense and inspection systems as well as in Medical and Industrial. 3. Acorda Therapeutics (ACOR) upgraded to Neutral from Sell at Goldman, with analyst Salveen Richter saying recent positive data for CVT-301 in Parkinson's removes a worst-case scenario with a potential 2018 market entry to offset Ampyra. 4. On Assignment (ASGN) upgraded to Outperform from Market Perform at Avondale, with analyst Randle Reece saying he expects IT staffing to to lead the U.S. staffing industry in 2017-18 growth, driven by agency staffing demand in large vertical markets such as technology and financial services, and emerging drivers. 5. Brady (BRC) upgraded to Buy from Neutral at Northcoast by analyst Keith Housum, who says he is confident guidance and consensus estimates will move higher given improving operations resulting in lower SG&A, improving revenue expectations and a strengthening balance sheet resulting in lower interest expense. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here
02/15/17
GSCO
02/15/17
UPGRADE
Target $22
GSCO
Neutral
Acorda Therapeutics upgraded to Neutral from Sell at Goldman
Goldman Sachs analyst Salveen Richter upgraded Acorda Therapeutics to Neutral saying recent positive data for CVT-301 in Parkinson's removes a worst-case scenario with a potential 2018 market entry to offset Ampyra. The analyst raised his price target for the shares to $22 from $16.
02/09/17
STFL
02/09/17
NO CHANGE
STFL
Acorda Therapeutics data positive, says Stifel
Stifel analyst Thomas Shrader says that the data on Acorda's CVT-301 drug was "clearly positive." The analyst raised his price target on the stock to $30 from $28 and keeps a Buy rating.
02/09/17
LEER
02/09/17
NO CHANGE
LEER
Market Perform
Acorda Therapeutics Phase 3 data 'solid,' says Leerink
Leerink analyst Paul Matteis notes that Acorda Therapeutics' positive Phase 3 data of CVT-301 showing a statistically significant improvement in motor function in patients with Parkinson's disease was mostly expected. While the analyst says the data is "solid," he points out that it was not "as pristine" as Phase 2. He reiterates a Market Perform on the shares.

TODAY'S FREE FLY STORIES

CXP

Columbia Property

$21.68

-0.27 (-1.23%)

20:50
03/27/17
03/27
20:50
03/27/17
20:50
Upgrade
Columbia Property rating change  »

Columbia Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

SPG

Simon Property

$166.15

-1.8 (-1.07%)

20:45
03/27/17
03/27
20:45
03/27/17
20:45
Conference/Events
Simon Property management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 27

    Apr

HALO

Halozyme

$14.27

0.74 (5.47%)

20:41
03/27/17
03/27
20:41
03/27/17
20:41
Conference/Events
Halozyme management to meet with Canaccord »

Meeting to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 01

    Apr

  • 06

    Jun

AYR

Aircastle

$23.44

0.03 (0.13%)

20:38
03/27/17
03/27
20:38
03/27/17
20:38
Conference/Events
Aircastle management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

NEE

NextEra Energy

$131.10

-1.7 (-1.28%)

20:30
03/27/17
03/27
20:30
03/27/17
20:30
Conference/Events
NextEra Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

M

Macy's

$27.93

-0.24 (-0.85%)

20:26
03/27/17
03/27
20:26
03/27/17
20:26
Conference/Events
Macy's management to meet with Guggenheim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

, HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Conference/Events
Heritage Oaks to host special shareholder meeting »

Special Shareholder…

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 15

    May

CCL

Carnival

$58.87

0.27 (0.46%)

, MKC

McCormick

$101.36

0.35 (0.35%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$58.87

0.27 (0.46%)

MKC

McCormick

$101.36

0.35 (0.35%)

DRI

Darden

$75.58

-1.13 (-1.47%)

FDS

FactSet

$174.55

-2.18 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    May

SYY

Sysco

$52.04

-0.77 (-1.46%)

20:17
03/27/17
03/27
20:17
03/27/17
20:17
Conference/Events
Sysco management to meet with Guggenheim »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

  • 20

    Jun

MNK

Mallinckrodt

$44.33

1.24 (2.88%)

20:13
03/27/17
03/27
20:13
03/27/17
20:13
Conference/Events
Mallinckrodt management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 08

    May

OGE

OGE Energy

$35.41

-0.28 (-0.78%)

20:10
03/27/17
03/27
20:10
03/27/17
20:10
Conference/Events
OGE Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

, CMCSK

Comcast

20:03
03/27/17
03/27
20:03
03/27/17
20:03
Periodicals
Comcast to expand streaming video service, Reuters says »

Comcast plans to rebrand…

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAR

Marriott

$93.17

-0.33 (-0.35%)

20:02
03/27/17
03/27
20:02
03/27/17
20:02
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

FBR

Fibria Celulose

$8.67

-0.22 (-2.47%)

19:58
03/27/17
03/27
19:58
03/27/17
19:58
Conference/Events
Fibria Celulose management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

DXC

DXC Technology

, HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Initiation
DXC Technology, HP Enterprise, CSC initiated at Goldman »

DXC Technology initiated…

DXC

DXC Technology

HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

CSC

CSC

$68.05

0.35 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 29

    Mar

  • 06

    Apr

  • 11

    Apr

  • 12

    Apr

  • 13

    Apr

  • 02

    May

  • 12

    Jun

TRI

Thomson Reuters

$43.56

-0.19 (-0.43%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Conference/Events
Thomson Reuters management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 28

    Apr

FIS

FIS

$80.41

0.29 (0.36%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Downgrade
FIS rating change at Goldman »

FIS downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$24.00

0.12 (0.50%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Conference/Events
Coupa Software management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 06

    Apr

ALK

Alaska Air

$95.00

0.3 (0.32%)

19:44
03/27/17
03/27
19:44
03/27/17
19:44
Conference/Events
Alaska Air management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

  • 04

    May

TIVO

TiVo

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Conference/Events
TiVo management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 10

    May

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

, SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Hot Stocks
Georgia finds 'low pathogenic' bird flu in commercial flock »

The Georgia Department of…

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

PPC

Pilgrim's Pride

$22.31

0.05 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 20

    Jun

KR

Kroger

$28.93

-0.17 (-0.58%)

19:37
03/27/17
03/27
19:37
03/27/17
19:37
Conference/Events
Kroger management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

VALE

Vale

$9.34

0.04 (0.43%)

19:30
03/27/17
03/27
19:30
03/27/17
19:30
Hot Stocks
Vale says Fabio Schvartsman appointed as CEO »

Vale announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSM

Nationstar

$15.05

0.1 (0.67%)

19:21
03/27/17
03/27
19:21
03/27/17
19:21
Initiation
Nationstar initiated at Wedbush »

Nationstar initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNVGY

Lenovo

$12.57

-0.03 (-0.24%)

19:14
03/27/17
03/27
19:14
03/27/17
19:14
Periodicals
Lenovo, Fujitsu postpone PC tie-up, Nikkei says »

Lenovo and Fujitsu will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.